Biomarkers in the development of novel disease-modifying therapies for osteoarthritis.
Identification and utilization of biomarkers is vitally important for the successful development of disease-modifying osteoarthritis drugs. Biochemical and imaging platforms hold great promise to deliver such biomarkers. Studies indicate a marked increase in biochemical products arising from the breakdown and biosynthesis of collagen, extracellular matrix and bone in osteoarthritis. These molecules have been associated with disease severity and may also have prognostic value as indicators of disease progression. However, issues including biological variability and lack of tissue specificity currently hinder the utility of these molecular markers in drug development. Imaging technologies hold great potential for sensitive and accurate measurement of disease-related structural damage. Drawbacks, including expense, need for validation and limited accessibility also limit the utility of these technologies. In this article, the potential value and challenges in developing and utilizing biomarkers in disease-modifying osteoarthritis drug development will be discussed.